Your session is about to expire
← Back to Search
Angiotensin II Receptor Blocker
Cohort 2: Telmisartan + Standard of Care Regimen for Prostate Cancer
Phase < 1
Waitlist Available
Led By Rodwell Mabaera, MD
Research Sponsored by Tyler J Curiel
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Participants must be able and willing to provide informed consent or have a surrogate capable of providing same.
Participants must be ≥18 years of age.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 months
Awards & highlights
Study Summary
This trial will test how well telmisartan works in treating prostate cancer in men.
Who is the study for?
Men over 18 with prostate cancer and a PSA level >1 ng/ml can join this trial. They must be stable on or likely to start standard treatments, able to monitor their blood pressure, consent themselves (or have someone who can), not need immediate treatment changes, and have normal or controlled high blood pressure that allows for telmisartan use.Check my eligibility
What is being tested?
This study is testing the safety of adding telmisartan to the usual prostate cancer treatments. Participants will either receive telmisartan alongside their standard care regimen or continue with just the standard care to see how well they tolerate the addition of telmisartan.See study design
What are the potential side effects?
Telmisartan may cause dizziness due to low blood pressure, fatigue, nausea, and an increased risk of high potassium levels. It might also affect kidney function and could interact with other medications used for controlling blood pressure.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I can give my consent or have someone who can consent for me.
Select...
I am 18 years old or older.
Select...
My PSA level is over 1 ng/ml.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 24 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Tolerability of oral telmisartan
Secondary outcome measures
Increase in tumor DNA damage
Other outcome measures
Reduction of blood prostate specific antigen
Trial Design
2Treatment groups
Experimental Treatment
Group I: Cohort 2: Telmisartan + Standard of Care RegimenExperimental Treatment2 Interventions
Patients will receive telmisartan with cabazitaxel or docetaxel without abiraterone), or telmisartan with docetaxal with abirateron or olaparib or rucaparib, or talazoparib plus enzalutamide.
Group II: Cohort 1: Telmisartan AloneExperimental Treatment1 Intervention
Patients will receive telmisartan alone.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Telmisartan
1999
Completed Phase 4
~14550
Find a Location
Who is running the clinical trial?
Tyler J CurielLead Sponsor
Rodwell Mabaera, MDPrincipal InvestigatorDartmouth Health
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Is enrollment still in progress for this trial?
"As per the information on clinicaltrials.gov, this study is no longer recruiting patients; it was initially posted in January 1st 2024 and last updated December 12th 2023. Luckily, there are still 1336 other trials that currently accept new participants."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger